Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.
Iniparib is a drug that was studied as a PARP inhibitor for treating triple-negative breast cancer. Iniparib was shown to be ineffective in treating triple-negative breast cancer. Researchers determined that this drug is not a true PARP inhibitor. It includes a chemical group that is not present in other PARP inhibitors that makes it difficult for iniparib to bind PARP.